Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
TORONTO, Feb. 27, 2024 -- Arch Biopartners Inc., , announced today that it had a pre-investigational new drug application meeting with the U.S. Food and Drug Administration Division of...